




# RESEARCH REPORT



## OTC/DTC INFECTIOUS DISEASE DIAGNOSTICS

Strategies and Trends for Over the Counter and Direct To Consumer. Forecasts by Application by Channel by Country. With Market Analysis, Executive Guides, and Market Opportunity Analysis

2023 to 2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides .....	21
1.1	Situation Analysis .....	22
1.2	Guide for Executives and Marketing Staff .....	24
1.3	Guide for Investment Analysts and Management Consultants.....	25
2	Introduction and Market Definition .....	26
2.1	What is OTC and DTC Testing?.....	27
2.2	OTC/DTC Testing – the quiet revolution in diagnostics .....	28
2.3	Self vs. Send – who knew? .....	29
2.4	Market Definition .....	30
2.4.1	Retail vs. Wholesale .....	30
2.4.2	OTC, DTC, HxV and HSG .....	30
2.4.3	Currency .....	31
2.4.4	Years .....	31
2.5	Methodology.....	32
2.5.1	Methodology .....	32
2.5.2	Sources.....	32
2.5.3	Authors .....	32
2.6	Perspective: Healthcare and the IVD Industry .....	34
2.6.1	Spending on Diagnostics .....	35
2.6.2	Important Role of Insurance for Diagnostics .....	37
3	The Infectious Diseases – Guide to the Pathogens.....	38
3.1	HIV - Human Immunodeficiency Virus (AIDS) .....	39
3.1.1	Virology .....	39

3.1.1.1	Classification .....	39
3.1.1.2	Structure and genome.....	40
3.1.1.3	Tropism.....	42
3.1.1.4	Replication cycle.....	45
3.1.1.5	Genetic variability .....	50
3.1.2	Diagnosis .....	52
3.1.3	Testing.....	53
3.1.3.1	Antibody tests .....	53
3.1.3.2	Point of Care Tests (POCT) .....	56
3.1.3.3	Antigen Tests .....	59
3.1.3.4	Nucleic acid-based tests (NAT) .....	59
3.1.3.5	Other tests used in HIV treatment.....	60
3.2	HBV – Hepatitis B.....	62
3.2.1	Virology .....	63
3.2.1.1	Genome .....	64
3.2.1.2	Pathogenesis.....	65
3.2.1.3	Hepatitis B virus replication .....	65
3.2.1.4	Serotypes and genotypes.....	66
3.2.2	Mechanisms .....	66
3.2.3	Diagnosis .....	67
3.2.4	Market Opportunity Analysis .....	68
3.3	HCV – Hepatitis C .....	69
3.3.1	Taxonomy.....	70
3.3.1.1	Structure .....	70
3.3.1.2	Genome .....	71
3.3.2	Molecular biology .....	72

3.3.3 Replication.....	73
3.3.4 Genotypes .....	75
3.3.4.1 Clinical importance.....	75
3.3.5 Market Opportunity Analysis .....	76
3.4 HPV - Human papillomavirus.....	77
3.4.1 Virology .....	79
3.4.1.1 E6/E7 proteins.....	79
3.4.1.2 Role in cancer.....	79
3.4.1.3 Research .....	80
3.4.1.4 Latency period .....	81
3.4.1.5 Clearance .....	81
3.4.2 Diagnosis .....	82
3.4.2.1 Cervical testing.....	82
3.4.2.2 Oral testing.....	84
3.4.2.3 Testing men .....	84
3.4.2.4 Other testing .....	85
3.4.3 Market Opportunity Analysis .....	86
3.5 Coronavirus .....	93
3.5.1 Severe acute respiratory syndrome (SARS) .....	95
3.5.2 Middle East respiratory syndrome (MERS) .....	96
3.5.2 COVID-19. The SARS CoV 2 Virus.....	98
3.5.2.1 Signs and symptoms.....	99
3.5.2.2 Transmission .....	100
3.5.2.3 Diagnosis .....	101
3.5.2.4 Prevention .....	103
3.5.2.5 Management.....	104

3.5.2.6	Prognosis.....	105
3.5.3	Pandemic Diagnostics .....	106
3.5.3.1	Risk Management – Spark and Spread .....	106
3.5.3.2	Dx Technology – Nucleic Acid Based .....	108
3.5.3.3	Dx Technology - Immunoassay.....	108
3.5.3.4	Time to Market and Preparedness Issues.....	109
3.6	Influenza.....	109
3.6.1	Flu.....	111
3.6.1.1	Types of virus .....	111
3.6.1.2	Influenzavirus A .....	111
3.6.1.3	Influenzavirus B .....	112
3.6.1.4	Influenzavirus C .....	112
3.6.1.5	Structure, properties, and subtype nomenclature .....	112
3.6.1.6	Replication .....	114
3.6.2	Testing.....	116
3.6.2.1	Advantages/Disadvantages of Molecular Assays.....	118
3.6.3	Market Opportunity Analysis .....	119
3.7	CT/NG - Chlamydia/Gonorhea .....	128
3.7.1	Gonorrhea .....	128
3.7.1.1	Diagnosis .....	129
3.7.1.2	Screening .....	129
3.7.2	Chlamydia .....	129
3.7.2.1	Diagnosis .....	130
3.7.2.2	Screening .....	131
3.7.3	Testing.....	132
3.7.3.1	Nucleic acid amplification tests (NAATs).....	132

3.7.3.2 Performance of NAAT Tests.....	141
3.7.4 Market Opportunity Analysis .....	142
3.8 UTI .....	144
3.8.1 Diagnosis .....	144
3.8.2 Testing.....	146
3.8.2.1 Nitrites test .....	146
3.8.2.2 Leukocytes test .....	147
3.8.3 Market Opportunity Analysis .....	148
3.9 GAS .....	149
3.9.1 Infectious Agents.....	149
3.9.2 Market Opportunity Analysis .....	151
3.10 RESP .....	152
3.10.1 Diagnosis .....	153
3.10.2 Market Opportunity Analysis .....	154
4 Industry Overview.....	156
4.1 Industry Participants.....	157
4.1.1 IVD Supplier.....	157
4.1.2 Independent lab specialized/esoteric .....	158
4.1.3 Independent lab national/regional.....	158
4.1.4 Independent lab analytical .....	159
4.1.5 Public National/regional lab .....	159
4.1.6 Hospital lab .....	159
4.1.7 Physician lab.....	160
4.1.8 Pharmacies .....	160
4.1.9 Audit body .....	161
4.2 The Clinical Laboratory Market Segments .....	162

4.2.1	Traditional Market Segmentation.....	162
4.2.2	Laboratory Focus and Segmentation.....	163
4.2.3	Segmenting the OTC/DTC Market .....	164
4.3	Industry Structure.....	166
4.3.1	Hospital Testing Share .....	166
4.3.2	Economies of Scale.....	166
4.3.3	Hospital vs. Central Lab .....	167
4.3.4	Physician Office Lab's.....	168
4.3.4.1	The Problem with POLS .....	168
4.3.5	Physician's and OCT/DTC .....	169
4.3.6	Pharmacies and OCT/DTC .....	169
4.3.6.1	The Diagnostic Plight of Pharmacies – Trying to do good.....	169
4.3.6.2	The Theranos Legacy .....	170
5	Market Trends .....	171
5.1	Factors Driving Growth .....	172
5.1.1	Privacy and Anonymity.....	172
5.1.2	The Internet Effect .....	172
5.1.3	Rapid Result .....	173
5.1.4	The Wellness Movement .....	173
5.1.5	The COVID-19 Impact.....	173
5.2	Factors Limiting Growth .....	174
5.2.1	Trust Factor .....	174
5.2.2	Infectious Disease is Declining But.....	176
5.2.3	Wellness Hurts.....	176
5.2.4	Economic Growth improves Living Standards .....	176
5.3	Diagnostic Technology Development .....	177

5.3.1	The Multiplex Paradigm Shift.....	177
5.3.2	NAT vs. Lateral Flow.....	179
5.3.3	The Unusual Role of GPS .....	179
5.3.4	Self and Send Competition .....	179
5.3.5	The Relationship to DTC Genetic .....	180
5.3.6	The Relationship to TeleHealth .....	181
5.3.7	Sample Collection – Who Knew?.....	181
6	OTC/DTC Infectious Disease Testing Recent Developments.....	182
6.1	Recent Developments – Importance and How to Use This Section .....	183
6.1.1	Importance of These Developments .....	183
6.1.2	How to Use This Section.....	183
6.2	DiagMetrics Developing Breath Assays.....	183
6.3	Co-Diagnostics Awarded \$2.3M for TB, HPV Tests .....	187
6.4	POC Developers Nuclein and Minute Molecular Dx Merge .....	187
6.5	ReadyGo Dx to Make MDx Testing a 'Snap' .....	188
6.6	Altratech Enters POC Space Supplanting PCR .....	193
6.7	FDA Authorizes First OTC Home Test for both Influenza and COVID-19 .....	197
6.8	Pharmacies Poised to Capture At-Home Diagnostics Category.....	198
6.9	How Labcorp, Abbott, BD, Siemens plan to expand home testing market .....	202
6.10	Morgan Health Invests in LetsGetChecked .....	204
6.11	New US\$ 1 price for HIV self-tests .....	206
6.12	Startup Detect to Roll Out Next-Gen Molecular Instrument .....	207
6.13	Diagnostics for the Real World Third-Generation POC Platform .....	210
6.14	Labcorp Partnering With Getlabs for Home Collection .....	213
6.15	Salignostics Closes Funding Round .....	214
6.16	Cue Health Targets DTC Market in 2022.....	215

6.17	Grip Molecular Developing Home Respiratory Panel .....	218
6.18	Mainz Biomed Developing Home ColoAlert Assay .....	222
6.19	MFB Fertility Closes Series A Financing Round.....	226
6.20	Continued Demand for SARS-CoV-2 Rapid Tests .....	226
6.21	Rapid Covid-19 Test Results Risk Going Uncounted .....	228
6.22	FDA Grants EUAs for Direct-to-Consumer Coronavirus Kit .....	230
6.23	Researchers Develop 15-Minute PCR System .....	231
6.24	Stanford Developing Low-Cost, At-Home, COVID-19 Saliva Test.....	233
6.25	Lucira Health Files for \$115M IPO .....	237
6.26	Spectrum Solutions Gets CE Mark for Saliva Collection Devices .....	238
6.27	Sherlock Biosciences Receives Gates Foundation Grant for COVID-19 Self-Test ....	239
6.28	LabCorp Receives EUA for OTC COVID-19 Test Home Collection Kit.....	240
6.29	FemtoDx Launches Rapid At-Home Test Development for COVID-19 .....	241
6.30	FDA approves first at-home coronavirus test.....	242
6.31	Free Home HIV Tests Detect More Infections .....	242
6.32	Biohacking trend supports self testing.....	243
6.33	PerkinElmer and EverlyWell to Expand U.S. At-Home Health Test Market.....	245
6.34	Mylan, Atomo Diagnostics Get WHO Prequalification Approval for HIV Self-Test ....	246
6.35	OraSure Technologies, Inc. Announces Two Acquisitions.....	247
6.36	Nigerian Govt Approves Alere HIV Self-Test Kit .....	250
6.37	Boots launches UTI test and treat service across 37 branches.....	251
6.38	Scanwell Health moves beyond home UTI testing .....	252
6.39	Healthy.io raises \$18 million for at-home urinalysis tests .....	253
6.40	LetsGetChecked collects \$30M more for at-home health testing .....	255
6.41	TestCard, a \$4 Urine Test Read by Smartphone .....	256
6.42	Digital Health Startup EverlyWell Raises \$50M.....	257

6.43	Thriva adds test-at-home kits for female hormone and cortisol stress .....	259
6.44	Tasso scores \$6.1M for patch-based home blood testing .....	261
6.45	DBS Systems HEMAXIS receives CE/IVD mark.....	262
6.46	Abbott HbA1c point-of-care test reliably diagnoses diabetes .....	263
7	Profiles of Key Diagnostic Testing Companies .....	265
7.1	1DropDiagnostics .....	266
7.2	Abbott Laboratories.....	267
7.3	Ador Diagnostics .....	269
7.4	ADT Biotech .....	270
7.5	Akronni Biosystems .....	271
7.6	Alveo Technologies.....	272
7.7	Antelope Dx.....	273
7.8	Applied BioCode .....	274
7.9	Atomo Diagnostics.....	276
7.10	Aus Diagnostics .....	277
7.11	Becton, Dickinson and Company .....	278
7.12	Binx Health .....	280
7.13	Biocartis .....	282
7.14	BioFire Diagnostics (bioMérieux) .....	283
7.15	bioMérieux Diagnostics.....	285
7.16	Bio-Rad Laboratories, Inc.....	287
7.17	Bosch Healthcare Solutions GmbH.....	289
7.18	Cepheid (Danaher) .....	290
7.19	Cue Health.....	292
7.20	Curetis N.V. / Curetis GmbH .....	294
7.21	DBS Systems .....	295

7.22	Detect .....	296
7.23	Diagenode Diagnostics .....	297
7.24	Diasorin S.p.A. ....	298
7.25	Ellume .....	300
7.26	Everywell .....	301
7.27	Getlabs.....	302
7.28	Grip Molecular Technologies .....	303
7.29	Healthy.io .....	304
7.30	Hologic .....	305
7.31	Inflamatix .....	307
7.32	Invetech.....	308
7.33	Janssen Diagnostics .....	309
7.34	Karius .....	310
7.35	Laboratory Corporation of America.....	311
7.36	Letsgetchecked .....	313
7.37	Lexogene .....	314
7.38	Lucira Health.....	315
7.39	Luminex Corp .....	316
7.40	Mbio Diagnostics.....	318
7.41	Mesa Biotech (Thermo Fisher) .....	319
7.42	MFB Fertility.....	320
7.43	Mobidiag (Hologic).....	321
7.44	myLabBox .....	322
7.45	Mylan.....	323
7.46	Nanomix.....	324
7.47	OraSure Technologies.....	325

7.48	Oxford Nanopore Technologies .....	326
7.49	Panagene .....	327
7.50	Primerdesign (Novacyt) .....	328
7.51	Prominex .....	329
7.52	Qiagen .....	330
7.53	QuantuMDx .....	332
7.54	Quest Diagnostics .....	333
7.55	Quidel.....	334
7.56	Randox Toxicology.....	336
7.57	Roche Molecular Diagnostics .....	337
7.58	Salignostics.....	339
7.59	Scanwell Health.....	340
7.60	SD Biosensor .....	341
7.61	Seegene.....	342
7.62	Seventh Sense Biosystems.....	343
7.63	Siemens Healthineers .....	344
7.64	T2 Biosystems.....	346
7.65	TestCard .....	347
7.66	Thermo Fisher Scientific Inc.....	348
7.67	Thriva .....	350
7.68	Visby Medical .....	351
7.69	XCR Diagnostics .....	353
8	Global Market Size .....	354
8.1	OTC/DTC ID Global Market Size by Country .....	355
8.1.1	OTC/DTC ID Global Market Size by Country Table.....	355
8.1.2	OTC/DTC ID Global Market Size by Country Chart .....	356

8.2 OTC/DTC ID Global Market Size by Syndrome .....	357
8.2.1 OTC/DTC ID Global Market Size by Syndrome Table .....	357
8.2.2 OTC/DTC ID Global Market Size by Syndrome Share by Year.....	358
8.2.3 OTC/DTC ID Global Market Size by Syndrome Base vs Final.....	359
8.2.4 OTC/DTC ID Global Market Size by Syndrome Base Year.....	360
8.2.5 OTC/DTC ID Global Market Size by Syndrome Final Year.....	361
8.2.6 OTC/DTC ID Global Market Size by Syndrome Segment Growth.....	362
8.3 OTC/DTC ID Global Market Size by Channel.....	363
8.3.1 OTC/DTC ID Global Market Size by Channel Table.....	363
8.3.2 OTC/DTC ID Global Market Size by Channel Share by Year .....	364
8.3.3 OTC/DTC ID Global Market Size by Channel Base vs Final .....	365
8.3.4 OTC/DTC ID Global Market Size by Channel Base Year .....	366
8.3.5 OTC/DTC ID Global Market Size by Channel Final Year.....	367
8.3.6 OTC/DTC ID Global Market Size by Channel Segment Growth .....	368
9 Global Market by Syndrome .....	369
9.1 Respiratory Market .....	370
9.1.1 Respiratory Market by Country Table .....	370
9.1.2 Respiratory Market Chart.....	371
9.2 STD Market .....	372
9.2.1 STD Market by Country Table .....	372
9.2.2 STD Market Chart.....	373
9.3 UTI Market .....	374
9.3.1 UTI Market by Country Table .....	374
9.3.2 UTI Market Chart.....	375
9.4 HxV Market .....	376
9.4.1 HxV Market by Country Table .....	376

9.4.2	HxV Market by Chart.....	377
9.5	Other Market.....	378
9.5.1	Other Market by Country Table .....	378
9.5.2	Other Market Chart.....	379
10	Global Market by Channel .....	380
10.1	OTC Market.....	381
10.1.1	OTC Market by Country Table.....	381
10.1.2	OTC Market Chart .....	382
10.2	DTC Market .....	383
10.2.1	DTC Market by Country Table .....	383
10.2.2	DTC Market Chart.....	384
10.3	HSG Market.....	385
10.3.1	HSG Market by Country Table .....	385
10.3.2	HSG Market Chart .....	386
11	Appendices.....	387
11.1	United States Medicare System: Clinical Laboratory Fees Schedule .....	388
11.2	FDA Approved Microbial Tests .....	482

## Table of Tables

Table 1 Classification of HIV Species.....	40
Table 2 HBV Tests - CMS Codes & Prices.....	69
Table 3 HCV Tests - CMS Codes & Prices .....	76
Table 4 HPV Clearance Rates .....	82
Table 5 HPV Tests - CMS Codes & Prices.....	87
Table 6 HPV Tests, Technology, Types .....	88
Table 7 Characteristics of Coronavirus Pandemic Infections .....	98
Table 8 COVID-19 Symptoms.....	100
Table 9 Types of Influenza Tests .....	116
Table 10 Influenza Tests - CMS Codes & Prices.....	119
Table 11 FDA Cleared Molecular Assays for Influenza .....	120
Table 12 FDA Cleared NAAT CTGC Tests .....	134
Table 13 CTGC NAAT Target Sequences and Possible False Reactions .....	139
Table 14 CT/NG Tests - CMS Codes & Prices .....	143
Table 15 GAS Panel BioFire .....	151
Table 16 BioFire RESP Panel.....	154
Table 17 Market Players by Type .....	157
Table 18 Clinical Laboratory Departments and Segments .....	162
Table 19 Laboratory Management Focus – Different Approaches .....	163
Table 20 Key Segmentation Variables Going Forward.....	164
Table 21 Possible Market Segments of OTC/DTC Market.....	164
Table 22 Five Factors Driving Growth.....	172
Table 23 Four Factors Limiting Growth .....	174

Table 24 Self vs. Send TAT.....	180
Table 25 OTC/DTC ID Global Market by Country/Region .....	355
Table 26 OTC/DTC ID Global Market by Syndrome .....	357
Table 27 OTC/DTC ID Global Market by Channel .....	363
Table 28 Respiratory Syndrome by Country .....	370
Table 29 STD Testing market by country .....	372
Table 30 UTI Testing market by country.....	374
Table 31 HxV Testing market by country.....	376
Table 32 Other Testing market by country.....	378
Table 33 OTC Market by Country .....	381
Table 34 DTC market by country .....	383
Table 35 HSG market by country.....	385
Table 36 Clinical Lab Fee Schedule .....	388

## Table of Figures

Figure 1 Global Healthcare Spending Map .....	35
Figure 2 The Lab Test Pie .....	36
Figure 3 HIV Virion .....	41
Figure 4 Diagram of the HIV Replication Cycle .....	45
Figure 5 The Structure of the HBV Virus.....	64
Figure 6 Hepatitis B Replication .....	65
Figure 7 Structure of the HCV Virus.....	71
Figure 8 HCV Replication Cycle .....	74
FIGURE 9 STRUCTURE OF CORONAVIRUSES .....	94
Figure 10 Structure of the Influenza Virion .....	113
Figure 11 Influenza Replication.....	114
Figure 12 Chart Death Rates and Infectious Disease Decline .....	175
Figure 13 The Multiplex Paradigm Shift.....	178
Figure 14 Market Size by Country - Key Countries.....	356
Figure 15 Chart of Global Market by Syndrome by Year .....	358
Figure 16 Syndrome Segment Shares Base vs Final.....	359
Figure 17 Syndrome Share Base Year.....	360
Figure 18 Syndrome Share Final Year.....	361
Figure 19 Syndrome Segment Growth Rates.....	362
Figure 20 Chart of Global Market by Channel by Year.....	364
Figure 21 Channel Segment Shares Base vs Final .....	365
Figure 22 Channel Share Base Year.....	366

Figure 23 Channel Share Final Year .....	367
Figure 24 Channel Segment Growth Rates .....	368
Figure 25 Chart - Respiratory market Growth.....	371
Figure 26 Chart – STD market Growht .....	373
Figure 27 Chart – UTI market Growth.....	375
Figure 28 Chart - HxV market Growth .....	377
Figure 29 Chart – Other market Growth .....	379
Figure 30 Chart - OTC market Growth .....	382
Figure 31 Chart – DTC market Growht .....	384
Figure 32 Chart – HSG market Growth.....	386